Physician profile
Daniel J Pierre
NPI 1659545051
$2,866.36
in general payments reported to CMS, 2019-2025
21 companies · $928 in 2025
The $928 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.87 · 2020: $240 · 2021: $281 · 2022: $410 · 2023: $468 · 2024: $443 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,740 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $410.77 | 2022-2025 | Hydrus Microstent, Clareon Panoptix Pro, Clareon |
| Mallinckrodt Hospital Products INC. | $393.45 | 2021-2025 | Acthar |
| Abbvie INC. | $314.20 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $215.66 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $213.77 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $165.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $159.97 | 2020 | |
| Allergan, INC. | $156.07 | 2020-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Dompe US, INC. | $122.82 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $91.94 | 2021-2023 | |
| Sight Sciences, INC. | $85.14 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $67.95 | 2021-2022 | |
| Harrow Eye, LLC | $61.12 | 2024-2025 | Vevye, Triesence, Iheezo |
| Thea Pharma INC. | $56.66 | 2023-2025 | Iyuzeh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $54.71 | 2021 | |
| Medline Industries LP | $48.08 | 2019 | |
| Omeros Corporation | $41.92 | 2021 | |
| Bausch & Lomb Americas INC. | $35.47 | 2025 | Alden Scleral Zenlens, Miebo, Xiidra |
| Genzyme Corporation | $24.24 | 2022 | |
| Amgen INC. | $21.77 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.